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Abstract
The Schnitzler syndrome (SS) is a rare and underdiagnosed entity that associates a chronic urticarial rash, monoclonal IgM
(or sometimes IgG) gammopathy and signs and symptoms of systemic inflammation. During the past 45years, the SS has
evolved from an elusive little-known disorder to the paradigm of a late-onset acquired auto-inflammatory syndrome.
Though there is no definite proof of its precise pathogenesis, it should be considered as an acquired disease involving
abnormal stimulation of the innate immune system, which can be reversed by the interleukin-1 receptor antagonist
anakinra. It clearly expands our view of this group of rare genetic diseases and makes the concept of auto-inflammation
relevant in polygenic acquired diseases as well. Increasing numbers of dermatologists, rheumatologists, allergologists,
haematologists and, more recently, nephrologists, recognize the SS. The aim of this review is to focus on kidney
involvement in the SS. Although the literature regarding kidney involvement in the SS is very poor it can be severe, as in
our own case here reported, leading us to recommend the systematic search for nephropathy markers in the SS.
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Auto-inflammatory diseases and the
Schnitzler syndrome
Many systemic diseases affect the kidney and the skin, including
relatively common immunologic and inflammatory disorders
(e.g. systemic lupus erythematosus, scleroderma, cryoglobulinae-
mia, Henoch–Schonlein purpura, microscopic polyangiitis and
atheroembolic disease), and rare hereditary conditions, such as
Fabry’s disease [1].
The Schnitzler syndrome (SS) is a rare and acquired systemic
disease, which bears in common many features with a group of
inherited diseases, referred to as auto-inflammatory syndromes
[2]. Liliane Schnitzler, a French dermatologist, first reported in
1972 the differential signs of the SS [3]. In the following years,
cases were reported from all over the world including North
America and Japan, but mostly from Europe. The European pre-
eminence is probably related to a better knowledge of this entity
in the Old World [2]. However, it remains a rare condition, when
considering that up to September 2014 only 281 cases have been
reported, with a male:female ratio of 1.5 [4]. Furthermore, a
review of 94 cases found a median age of onset of 51 years, and
only four patients developed symptoms before the age of
35 years [5]. In 2001, Lipsker et al. reported four cases and
Received:March 14, 2017; Editorial decision: June 15, 2017
VC The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
723
Clinical Kidney Journal, 2017, vol. 10, no. 6, 723–727
doi: 10.1093/ckj/sfx077
Advance Access Publication Date: 26 July 2017
CKJ Review
performed an extensive literature review, which allowed them
to establish diagnostic criteria [6].
Lipsker’s diagnostic criteria for the SS define the urticarial
skin rash and monoclonal IgM component (or IgG: variant type)
as ‘obligate criteria’ and at least two of the following criteria as
‘minor’: fever, arthralgia or arthritis, bone pain, palpable lymph
nodes, liver or spleen enlargement, elevated erythrocyte sedi-
mentation rate, leucocytosis and abnormal findings on bone
morphologic investigations [6]. The more recent Strasbourg diag-
nostic criteria for the SS define the chronic urticarial rash and
monoclonal IgM or IgG as ‘obligate criteria’; whereas recurrent
fever, objective findings of abnormal bone remodelling with or
without bone pain, a neutrophilic dermal infiltrate on skin
biopsy, leucocytosis and/or elevated C-reactive protein (CRP) are
considered ‘minor criteria’ [4]. Then, the diagnosis of the SS is
considered ‘definite’ if the two obligate criteria and at least two
minor criteria (with IgM gammopathy), or three minor criteria
(with IgG gammopathy), are met; the diagnosis of the SS is con-
sidered ‘probable’ if the two obligate criteria and at least one
minor criterion (with IgM gammopathy), or two minor criteria
(with IgG gammopathy), are met [4]. A multicentre study was
conducted between 2009 and 2014 in 14 hospitals in which
patients with the SS were followed up [7]. The authors compared
the sensitivities and the specificities of the Lipsker [6] and the
Strasbourg criteria [4]. Sensitivity and specificity of the Lipsker
criteria were 100% and 97%, respectively. For the Strasbourg crite-
ria, sensitivity for definite and probable diagnosis was 81% and
93%, respectively, with a corresponding specificity of 100% and
97%. The conclusion of the study was that diagnostic criteria cur-
rently in use to diagnose the SS are reliable [7].
In their article, Lipsker et al. included the chronic infantile
neurological cutaneous and articular syndrome (CINCA)/neonatal
onset multi-inflammatory disease (NOMID) and the Muckle–
Wells syndrome in the differential diagnosis and thus pointed for
the first time to similarities between the SS and the auto-
inflammatory syndrome, of which the latter are a paradigm [6].
Indeed, the CINCA syndrome, the Muckle–Wells syndrome and
familial cold auto-inflammatory syndrome are different pheno-
types of the cryopyrin-associated periodic syndromes (CAPS),
monogenic diseases involving the innate immune system. Their
pathophysiology implies exaggerated activation of the inflamma-
some, an intracellular multi-protein complex, interleukin-1 (IL-
1)- synthesizing cellular machinery, in response to cell stress [8].
Since their definition, inflammasome disorders have been linked
to an increasing number of diseases, in which different factors
lead to the activation of innate immune cells, causing tissue
damage in the absence of autoantigens and autoantibodies.
Many inflammasomopathies, such as CAPS, familial
Mediterranean fever (FMF), SS, hyper-IgD syndrome (HIDS), peri-
odic fever, aphthous stomatitis, pharyngitis and cervical adenitis
(PFAPA) syndrome and deficiency of IL-1 receptor antagonist
(DIRA) [9], include skin signs among the main features. As far as
our clinical activity in the field of auto-inflammatory diseases
(R.M.) is concerned, our database (1997–2017) includes 460
patients affected by FMF, 80 patients affected by the PFAPA syn-
drome, 30 patients affected by other auto-inflammatory fevers
(TRAPS, CAPS, MVKD, NLRP12-related fevers) and 6 patients
affected by the SS. None of these cases has ever been published.
Inhibition of the inflammasome pathway may be a target for
future therapies as demonstrated by the efficacy of IL-1 inhibi-
tors in CAPS. Since the SS shares many features with the CINCA
syndrome, anakinra, an IL-1 inhibitor, was also tried in the for-
mer syndrome and it proved to be the first really efficient treat-
ment of the SS [2]. Besada and Nossent reviewed the literature
(in 2010) concerning anakinra treatment in the SS: 24 patients
had been successfully treated with anakinra; furthermore,
‘seven out of seven patients, that either interrupted or used
anakinra every other day, had relapse of their symptoms within
24–48h; anakinra was restarted in all patients with the same
clinical efficiency’ [10].
The aim of this review is to focus on kidney involvement in
the SS.
Kidney involvement in the SS
The literature regarding kidney involvement in the SS is very
poor (Table 1). O’Hare et al. reported the case of a 34-year-old
white male affected by urticarial vasculitis (skin biopsy showed
leucocytoclastic vasculitis), renal insufficiency (serum creati-
nine 2.3mg/dL) with monoclonal gammopathy (a small IgG-k
spike on serum protein electrophoresis) [1]. This patient was
markedly hypocomplementaemic and the kidney biopsy find-
ings were characterized by an immune complex-mediated tubu-
lointerstitial nephritis associated with light chain deposition [1].
Prednisone was started, then, as prednisone was tapered, myco-
phenolate mofetil 1000mg twice a day was administered. The
serum creatinine settled in the 2.0–2.4mg/dL range [1].
Weshoff et al. reported the case of a 63-year-old male
affected by the SS (he had been suffering from chronic urticarial,
myalgia, malaise and severe bone pain for almost 10 years).
Monoclonal IgM gammopathy was detected; histology of urtica-
rial lesions was compatible with urticarial vasculitis [11]. The
patient was normocomplementaemic and his kidney function
was only moderately reduced, and glomerulonephritis was
deemed improbable since serological findings were normal and
there was no proteinuria; therefore, no kidney biopsy was per-
formed. Different treatment modalities, including antihist-
amines, corticosteroids, azathioprine, colchicine, the cytostatic
agent trofosfamide and mycophenolate mofetil, were not suffi-
cient to control the patient’s symptoms. Interferon a-2a com-
bined with six cycles of plasmapheresis achieved only initial
improvement. The patient experienced improvement of renal
function after treatment with the chimeric anti-CD20 antibody
rituximab [11].
Iwafuchi et al. reported the case of a 62-year-old male with a
6-year history of intermittent urticaria with low-grade fever and
recent leg oedema. Protein immunoelectrophoresis revealed an
IgM j-paraprotein in the serum; urinary protein was 4–5g/24h [12].
Table 1. Summary of the clinical cases reporting kidney involvement in the SS
Authors [reference] Age and gender Histologic findings of kidney biopsy
Serum creatinine
level (mg/dL)
O’Hare et al. [1] 34-year-old male Diffuse tubulointerstitial nephritis associated with light chain deposition 2.4
Weshoff et al. [11] 63-year-old male Kidney biopsy was not performed 1.6
Iwafuchi et al. [12] 62-year-old male Membranous nephropathy 1.0
Basile et al. (our case) 56-year-old male Type I membranoproliferative glomerulonephritis 8.5
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The histologic findings of the kidney biopsy were compatible with
a secondary form of membranous nephropathy. He was treated
with pulse intravenous methylprednisolone of 0.5g for 3 days, fol-
lowed by an oral prednisolone regimen [12].
Lastly, we report here our own clinical experience about kid-
ney involvement in the SS: as already said, our database
includes six patients affected by the SS. Five of them had nor-
mal kidney function, neither proteinuria nor haematuria. Only
two out of the five patients had anomalies linked to the gamm-
opathy (one patient had traces of cryoglobulinaemia with no C4
consumption, the other a high j/k ratio without Bence–Jones
proteinuria). The sixth case is worthy of being extensively
reported because of a very severe kidney involvement: a 56-
year-old white male had been in good health until the age of 44,
when he had the first episode of polyarthralgias and high spik-
ing fever of variable duration. The clinical picture regressed
within a week by means of the administration of paracetamol
and antibiotics. Since then, several similar episodes occurred at
intervals of approximately 6months and lasting about 1week,
complicated by the onset of skin rash: each of these episodes
was treated successfully by oral diclofenac. Laboratory tests
during the acute episodes showed increased levels of some
inflammatory markers that returned to normal in the periods of
wellness. Skeleton X-rays and total body computed tomography
were normal too. When the patient was 47 years old (in 2008), a
first episode of non-oliguric acute kidney injury occurred
(serum creatinine 2.0mg/dL); supportive care and oral diclofe-
nac were able to restore his kidney function to normal. When
the patient was 51 years old (in 2012), the first admission to our
unit was done because of a second episode of oliguric acute kid-
ney injury (serum creatinine 1.7mg/dL) associated with polyar-
thralgias, fever and skin rash. The dermatologist described the
picture as urticarial non-itching erythema, completely different
from a vasculitic erythema, most prominent on the trunk, arms
and legs, sparing the palms, soles, head and neck (Figure 1).
Increased levels of some inflammatory markers, notably
leucocytosis and CRP, were detected. Serum complement (C3
and C4) levels were very low; serum ANA, ANCA, ENA and anti-
bodies to dsDNA levels were normal; cryoglobulins were not
detected. For the first time a monoclonal IgG-k gammopathy
was detected. He underwent a kidney biopsy, which showed
the histologic picture of type I membranoproliferative glomeru-
lonephritis (Figures 2 and 3). Pulse intravenous methylpredniso-
lone (15mg/kg/day) for 3 days was successful in restoring
kidney function to normal. The patient was prescribed a
long-term outpatient treatment including low-dose steroids
and immunosuppressive drugs (among them cyclosporine and
azathioprine). This treatment was unable to prevent the occur-
rence of new episodes, characterized by the same cohort of clin-
ical signs and symptoms and laboratory data as described
above. Specifically, the occurrence of acute kidney injury led to
four admissions in our unit (in 2013, 2014, 2015 and 2016) with a
serum creatinine level ranging from 2.8 to 8.5mg/dL. During the
last hospitalization in 2016 anuria and the highest serum creati-
nine level (8.5mg/dL) occurred, requiring renal replacement
therapy (five haemodialysis sessions). Pulse intravenous meth-
ylprednisolone (15mg/kg/day) for 3 days was successful in
restoring kidney function to normal in all four hospital admis-
sions. We finally made the diagnosis of the SS in March 2016.
Then, a long-term treatment with subcutaneous daily adminis-
tration of the IL-1 receptor antagonist anakinra (100mg/day)
was prescribed. The patient decided not to adhere to this pre-
scription, but accepted to be treated at the very early beginning
of symptoms of a new potential episode with the immediate
subcutaneous administration of anakinra. Actually, two new
episodes occurred in October 2016 and February 2017: they were
treated successfully with three daily doses of anakinra (100mg/
day) and did not require any hospital admission. Furthermore,
as of today, kidney function is normal.
Discussion
The SS is characterized by a recurrent febrile rash, joint and/or
bone pain, enlarged lymph nodes, fatigue, a monoclonal IgM
component, leucocytosis and systemic inflammatory response
[2]. A monoclonal IgM component is the biological hallmark of
the disease; variant cases of the IgG subtype constitute 7% of
the reported cases [4]. Diagnosis of the SS relies on a combina-
tion of clinical, biological and radiological findings as well as on
exclusion of another cause. Especially, the following diseases/
entities need to be excluded: cryoglobulinaemia, hypocomple-
mentaemic urticarial vasculitis, adult-onset Still’s disease, sys-
temic lupus erythematosus, angioedema, and haematological
disorders such as lymphoma or IgM gammopathies of undeter-
mined significance (MGUS) [4]. Furthermore, a spectacular and
immediate response to anakinra is another finding that sup-
ports the diagnosis, as already suggested by Gilson et al. [13].
About 15–20% of patients with the SS will develop a lympho-
proliferative disorder, a prevalence shared with other patients
with MGUS [14]. AA amyloidosis is a concern in untreated
Fig. 1. The typical rash of the SS, which corresponds to a neutrophilic urticarial dermatosis: red eruptions consisting of flat macules are visible on the back and
abdomen.
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patients [5]. The reviews performed by Lipsker et al. in 2001, de
Koning et al. in 2007 and de Koning et al. in 2014 summarize
most published cases [4–6].
Antihistamines are not effective in treating the hives in this
condition. It may respond to immunosuppressive drugs such as
corticosteroids, cyclo-oxigenase inhibitors, interferon a, IL-1 recep-
tor antagonist anakinra, pefloxacin, colchicine, cyclosporine or tha-
lidomide. The hives may respond to treatment with PUVA, and the
bone pain may respond to bisphosphonates. The IL-1 receptor
antagonist anakinra relieves all symptoms within hours after the
first injection [10]. Because the SS is so rare, the efficacy of different
treatments cannot be compared using statistics. Nevertheless, case
studies provide evidence that anakinra is much more effective for
the SS than any other drug, and that the improvement in symp-
toms associated with this treatment is dramatic [10].
Theories concerning the pathophysiology of the SS include
hypothetical autoimmune properties of the paraprotein, a
haematological origin and more recently, interference with the
inflammasome, the activator of cytokines of innate immunity [4].
After the recognition of the SS as a potential auto-inflammatory
disorder, research focused on the role of pro-inflammatory cyto-
kines, IL-1b in particular [15, 16]. The effect of the IL-1 receptor
antagonist anakinra provided the first evidence for the crucial
role IL-1 plays in the pathophysiology of recurrent fever in the SS
[15, 16]. The recurrence of the systemic inflammation, due to IL-
1b over-activation, in presence of the monoclonal gammopathy,
is the most puzzling aspect of the SS. Accumulating data suggest
that the monoclonal gammopathy is caused by the systemic
inflammation rather than vice versa [4].
In conclusion, during the past 45 years, the SS has evolved
from an elusive little-known disorder to the paradigm of a late-
onset acquired auto-inflammatory syndrome. Though there is
no definite proof of its precise pathogenesis, it should be con-
sidered as an acquired disease involving abnormal stimulation
of the innate immune system, which can be reversed by the IL-1
receptor antagonist anakinra. It clearly expands our view of this
group of rare genetic diseases and makes the concept of auto-
inflammation relevant in polygenic acquired diseases as well
[2]. Increasing numbers of dermatologists, rheumatologists,
allergologists, haematologists and, more recently, nephrolo-
gists, recognize the SS. Although the literature regarding kidney
involvement in the SS is very poor however, it can be severe, as
in our own case here reported, leading us to recommend the
systematic search for nephropathy markers in the SS.
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